{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-008321","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","discovered_at":"2026-06-02T20:03:00.363611+00:00","generated_at":"2026-06-02T20:04:10.020836+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"ADC Therapeutics shareholders approve capital range increase, equity plan expansion at 2026 AGM","bullets":["Approved increase in authorized shares under 2019 Equity Incentive Plan: 46.6M for, 18.9M against.","Capital range expanded to CHF 10.4M lower / CHF 15.6M upper limit.","Conditional share capital for financing increased from 38.0M to 48.0M shares.","Board compensation capped at $2.5M; executive fixed $2.6M + variable $5.5M.","All nine director nominees reelected; all 12 proposals passed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-008321","json":"https://secwatch.observer/filing/0000950103-26-008321.json","markdown":"https://secwatch.observer/filing/0000950103-26-008321.md","text":"https://secwatch.observer/filing/0000950103-26-008321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/dp247757_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:04:10.020836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ab40d6d138120574e96ba7d805eb8674632a067","claim":"ADC Therapeutics SA shareholders approved Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as t at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.5},{"claim_id":"110f1c90c9145b002c05b59342e411c734502562","claim":"ADC Therapeutics SA shareholders approved Approving, on an advisory basis under Swiss law, the compensation report at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #2 : Approving, on an advisory basis under Swiss law, the compensation report The shareholders approved, in a non-binding advisory vote, the compensation report for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 64,289,299 1,242,782 3,815,289 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"1a1dd51b508d64e8ed72291fb4598d2ba09a6b7a","claim":"ADC Therapeutics SA shareholders approved Approving the management report, annual financial statements and consolidated financial statements at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #1 : Approving the management report, annual financial statements and consolidated financial statements The shareholders approved the management report, the annual financial statements and the consolidated financial statements for the year ended December 31, 2025 and acknowledged the auditors’ report for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,705,454 5,910 3,889,590 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"3b2bfa4e6ad7ebd4dab119a54f61c10b4dc1b1c1","claim":"ADC Therapeutics SA shareholders approved Reelecting the auditors at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #8 : Reelecting the auditors The shareholders reelected PricewaterhouseCoopers SA as the statutory auditor and independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,747,180 31,325 3,822,449 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"3bffc3dad991a209463707636395918f3af29e9f","claim":"ADC Therapeutics SA shareholders approved Reelecting compensation committee members at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #6 : Reelecting compensation committee members The shareholders reelected the following members of the compensation committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: NAME FOR AGAINST ABSTAIN BROKER NON-VOTES Robert Azelby 65,136,589 388,421 3,822,360 14,253,584 Peter Hug 65,014,833 469,178 3,863,359 14,253,584 Victor Sandor 65,145,109 380,752 3,821,509 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"4bc2faeb988a3a214dc84759152632a041fb644f","claim":"ADC Therapeutics SA shareholders approved Discharging the members of the board of directors and the executive committee from liability at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #3 : Discharging the members of the board of directors and the executive committee from liability The shareholders approved that the members of the board of directors and the executive committee be discharged from liability for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 63,695,590 86,523 3,966,182 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"7bf4be04ddcfd74c76cc2b8f6dbe64220338e31d","claim":"ADC Therapeutics SA shareholders approved Reelecting the Independent Proxy at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #7 : Reelecting the Independent Proxy The shareholders reelected PHC Notaires, in Lausanne, Switzerland, as the Independent Proxy for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,756,534 17,712 3,826,708 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"882517664fa64e0e91f6f659ffe6527ecc779193","claim":"ADC Therapeutics SA shareholders approved Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #9 : Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee The shareholders approved, on a binding basis under Swiss law, that (i) the maximum aggregate amount of compensation for the members of the board of directors for the period between the Annual Meeting and the 2027 annual general meeting of shareholders be set at $2,500,000 (Proposal #9a), (ii) the maximum aggregate amount of fixed compensation for the members of the executive committee for the year ending December 31, 2027 be set at $2,600,000 (Proposal #9b) and (iii) the maximum aggregate amount of variable compensation for the members of the executive committee for the year ending December 31, 2026 be set at $5,500,000 (Proposal #9c). The voting results were as follows: PROPOSAL FOR AGAINST ABSTAIN BROKER NON-VOTES #9a 48,456,972 16,977,874 3,912,524 14,253,584 #9b 64,981,047 439,267 3,927,056 14,253,584 #9c 64,541,036 883,352 3,922,982 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"9d6d59f0aa7cebe79b2c826ab36db11800e9500d","claim":"ADC Therapeutics SA shareholders approved Approving the appropriation of the financial results at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #4 : Approving the appropriation of the financial results The shareholders approved that the net loss for the year ended December 31, 2025 be carried forward. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,774,946 8,511 3,817,497 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"b6e389bd969a6999f35fce9a669dbef715d317eb","claim":"ADC Therapeutics SA shareholders approved Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #10 : Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers The shareholders approved, on an advisory basis under U.S. law, the compensation of the Company’s named executive officers, as disclosed in “Executive Compensation” and the related compensation tables and narrative disclosure in the proxy statement. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 64,172,306 1,271,205 3,903,859 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"bb5dab9fb9bf0b4c75fc1bcaae10be6bfdeea819","claim":"ADC Therapeutics SA shareholders approved Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #11 : Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The shareholders approved an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 46,624,648 18,904,924 3,817,798 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95},{"claim_id":"d2e176a86086bd7c2c5578700fb8e92c788ca616","claim":"ADC Therapeutics SA shareholders approved Reelecting directors at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: NAME FOR AGAINST ABSTAIN BROKER NON-VOTES Ron Squarer 65,109,377 416,194 3,821,799 14,253,584 Robert Azelby 65,094,726 429,835 3,822,809 14,253,584 Jean-Pierre Bizzari 63,631,611 1,852,731 3,863,025 14,253,587 Timothy Coughlin 65,198,947 327,049 3,821,374 14,253,584 Peter Hug 64,927,601 556,545 3,863,224 14,253,584 Ameet Mallik 65,133,390 387,036 3,826,944 14,253,584 Viviane Monges 64,918,973 556,772 3,871,625 14,253,584 Tyrell Rivers 64,796,462 729,534 3,821,374 14,253,584 Victor Sandor 65,151,213 373,932 3,822,225 14,253,584","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-253825","ticker":"ACIW","company_name":"ACI WORLDWIDE, INC.","filed_at":"2026-06-02T21:08:06+00:00","headline":"ACI Worldwide annual meeting approves all proposals including director elections","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.0,"calibrated_materiality_score":0.0,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253825","json":"https://secwatch.observer/filing/0001193125-26-253825.json","markdown":"https://secwatch.observer/filing/0001193125-26-253825.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/935036/000119312526253825/0001193125-26-253825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/935036/000119312526253825/d92029d8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"The stockholders approved, on an advisory basis, the named executive compensation as described in the 2026 Proxy Statement.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/935036/000119312526253825/0001193125-26-253825-index.htm"}},{"accession":"0001193125-26-253604","ticker":"KYTX","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-06-02T20:30:16+00:00","headline":"Kyverna Therapeutics shareholders elect Ian Clark and Christi Shaw as Class II directors, ratify BDO USA auditor","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253604","json":"https://secwatch.observer/filing/0001193125-26-253604.json","markdown":"https://secwatch.observer/filing/0001193125-26-253604.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/0001193125-26-253604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/kytx-20260527.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"Director Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 31,505,902 3,255,231 9,225,874 Christi Shaw 34,528,865 232,268 9,225,874","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/0001193125-26-253604-index.htm"}},{"accession":"0001104659-26-069461","ticker":"PARK","company_name":"Park Dental Partners, Inc.","filed_at":"2026-06-02T20:05:32+00:00","headline":"Park Dental Partners announces shareholder voting results at 2026 annual meeting","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.1,"calibrated_materiality_score":0.1,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069461","json":"https://secwatch.observer/filing/0001104659-26-069461.json","markdown":"https://secwatch.observer/filing/0001104659-26-069461.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2069604/000110465926069461/0001104659-26-069461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2069604/000110465926069461/tm2616585d1_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2069604/000110465926069461/0001104659-26-069461-index.htm"}},{"accession":"0001104659-26-069446","ticker":"SGA","company_name":"SAGA COMMUNICATIONS INC","filed_at":"2026-06-02T20:00:26+00:00","headline":"Saga Communications shareholders elect all 7 directors, approve say-on-pay and auditor ratification","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069446","json":"https://secwatch.observer/filing/0001104659-26-069446.json","markdown":"https://secwatch.observer/filing/0001104659-26-069446.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/886136/000110465926069446/0001104659-26-069446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886136/000110465926069446/sga-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"The seven nominees for election as directors for the ensuing year, and until their successors are elected and qualified, were elected and received the following votes:","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/886136/000110465926069446/0001104659-26-069446-index.htm"}},{"accession":"0001104659-26-068996","ticker":"XBP","company_name":"XBP Global Holdings, Inc.","filed_at":"2026-06-01T21:00:49+00:00","headline":"XBP Global Holdings annual meeting elects directors, approves auditor and say-on-pay","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068996","json":"https://secwatch.observer/filing/0001104659-26-068996.json","markdown":"https://secwatch.observer/filing/0001104659-26-068996.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/0001104659-26-068996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/tm2616124d2_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"Proposal 4 — To consider and vote upon a proposal to approve, on an advisory (non-binding) basis, the frequency of future say-on-pay votes: Votes For 1 Year Votes For 2 Years Votes For 3 Years Votes Abstained Broker Non-Votes 9,200,507 333 488 332,030 577,920","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/0001104659-26-068996-index.htm"}},{"accession":"0001628280-26-039483","ticker":"AXON","company_name":"AXON ENTERPRISE, INC.","filed_at":"2026-06-01T20:10:40+00:00","headline":"Axon shareholders elect all 9 director nominees and approve say-on-pay at 2026 annual meeting","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039483","json":"https://secwatch.observer/filing/0001628280-26-039483.json","markdown":"https://secwatch.observer/filing/0001628280-26-039483.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/0001628280-26-039483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/axon-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"Proposal No. 2 — Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers ( “ Say-on-Pay ” ) The non-binding advisory vote to approve the compensation of the Company’s named executive officers was approved as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 54,903,698 6,239,017 112,972 11,665,236","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/0001628280-26-039483-index.htm"}},{"accession":"0001828536-26-000052","ticker":"NRGV","company_name":"Energy Vault Holdings, Inc.","filed_at":"2026-06-01T15:36:32+00:00","headline":"Energy Vault shareholders elect three Class II directors and ratify BDO USA as auditor","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001828536-26-000052","json":"https://secwatch.observer/filing/0001828536-26-000052.json","markdown":"https://secwatch.observer/filing/0001828536-26-000052.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828536/000182853626000052/0001828536-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828536/000182853626000052/nrgv-20260529.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"Proposal 2 - Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Votes Abstaining Broker Non-Votes 127,775,985 168,810 59,341 —","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1828536/000182853626000052/0001828536-26-000052-index.htm"}},{"accession":"0001628280-26-039250","ticker":"RUN","company_name":"Sunrun Inc.","filed_at":"2026-05-29T22:01:11+00:00","headline":"Sunrun annual meeting elects nine directors, approves say-on-pay, ratifies auditor","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039250","json":"https://secwatch.observer/filing/0001628280-26-039250.json","markdown":"https://secwatch.observer/filing/0001628280-26-039250.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469367/000162828026039250/0001628280-26-039250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469367/000162828026039250/run-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","comparable_excerpt":"Proposal 2: Advisory vote on the compensation of the Company’s named executive officers.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1469367/000162828026039250/0001628280-26-039250-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}